PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL
Abstract
Authors
AG Olsson MM Jensen SK Gandhi KM Fox T Paulsson